NASDAQ:NAUT
Nautilus Biotechnology, Inc.
Nautilus Biotechnology, Inc. reported net income of −$59.0M in fiscal 2025. Free cash flow was −$52.0M, and the diluted share count rose 0.7%.Summary generated from Nautilus Biotechnology, Inc.'s SEC filings. Latest annual report filed Feb 26, 2026.
Key statistics
Fiscal 2025 from SEC filings. MethodologyRevenue (FY25)n/a
Revenue growthn/a
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating marginn/a
Net marginn/a
ROICn/a
Return on equity−32.3%
Debt / equityn/a
Free cash flow−$52.0M
FCF marginn/a
Share count change+0.7%
Financials
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | n/a | n/a | n/a | n/a | n/a |
| Operating income | n/a | n/a | n/a | n/a | n/a |
| Net income | −50 | −58 | −64 | −71 | −59 |
| Free cash flow | −42 | −48 | −54 | −61 | −52 |
Recent filings
- 8-KEntry into a material agreement
Sep 11, 2026 - 10-QQuarterly report for the period ended Jun 30, 2026
Jul 28, 2026 - 8-KResults of operations and financial condition
Jul 28, 2026 - 4Insider transaction report
Jun 22, 2026 - 4Insider transaction report
Jun 22, 2026 - 8-KResults of a shareholder vote
Jun 18, 2026 - DEF 14AProxy statement
Apr 28, 2026 - 10-QQuarterly report for the period ended Mar 31, 2026
Apr 28, 2026